Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144638 | 0.91 | NPC1 (0.46) | GLSNPC1CNR2CNR1ACHE | |
| SCHEMBL2592930 | 0.81 | GLS (0.36) | GLSNPC1 | |
| SCHEMBL30908134 | 0.81 | NPC1 (0.38) | GLSNPC1MAPTRAB9APOLB | |
| SCHEMBL18188212 | 0.80 | GLS (0.37) | GLSMAPTRAB9AALDH1A1 | |
| SCHEMBL28991115 | 0.79 | BRD4 (0.39) | GLSMAPTLMNA | |
| SCHEMBL28991142 | 0.79 | GLS (0.34) | GLSNPC1SMN1; SMN2 | |
| SCHEMBL18188365 | 0.79 | GLS (0.36) | GLSMAPTRAB9AALDH1A1 | |
| SCHEMBL30076388 | 0.79 | GLS (0.34) | GLSNPC1SMN1; SMN2 | |
| SCHEMBL31038849 | 0.79 | DGAT1 (0.35) | GLSNPC1MAOB | |
| SCHEMBL3514316 | 0.79 | CHEK1 (0.43) | GLSNPC1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| EP-4144736-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| EP-3901153-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | disclosed |
| CN-107835814-B | Azabenzimidazoles and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3288940-B9 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3288940-B1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3288940-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176460-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GLS 576/4885NPC1 2055/4885CNR2 271/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GLS 655/4885NPC1 2011/4885CNR2 263/4885 |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | GLS 314/4885NPC1 367/4885CNR2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.